Experience

Davis Polk advised the dealer manager on a cash tender offer by Bristol-Myers Squibb Company for any and all of its 5.875% notes due 2036, 6.125% notes due 2038 and 6.875% debentures due…

Davis Polk advised the joint book-running managers in connection with a $260.8 million SEC-registered offering of 3,622,500 shares of common stock of Loxo Oncology, Inc. The common stock is…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Cardinal Health, Inc. of $1 billion aggregate principal amount of its 1.948% notes due…

Davis Polk advised the sole underwriter in connection with the public offering of 3,450,000 shares of common stock of NanoString Technologies, Inc. The common stock is listed on the NASDAQ…

Davis Polk advised the joint book-running managers in connection with the $112.5 million public offering of common stock of Achaogen, Inc. The common stock is listed on the NASDAQ…

Davis Polk advised the sole book-running manager of a $359.35 million SEC-registered offering of 5,000,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Alnylam’s common stock is…

Davis Polk advised the representative of the several underwriters in connection with a secondary offering of 7,000,000 shares of Class A common stock of Evolent Health, Inc. by certain of…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $350 million aggregate principal amount of its 0.75% senior convertible notes due…

Davis Polk advised the underwriters in connection with an SEC-registered offering by AMAG Pharmaceuticals, Inc. of $300 million aggregate principal amount of its 3.25% convertible…

Davis Polk advised the joint book-running managers in connection with a $2.25 billion registered offering by Eli Lilly and Company of $750 million principal amount of its 2.350% notes…